Key Takeaway: Precision BioSciences has reported its third quarter 2024 financial results, highlighting the approval of its first Clinical Trial Application for PBGENE-HBV. This marks a significant step towards initiating first-in-human trials for chronic hepatitis B treatment. The phase 1 clinical program has commenced in Moldova, with patient screening currently in progress.
Price reaction · baseline $6.5 (2024-11-21 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+11.7%
day 1
+11.4%
day 3
+9.4%
Market Sentiment Analysis
POSITIVE FACTORS
Approval received for first Clinical Trial Application.
Advancement of PBGENE-HBV into first-in-human trials.
Patient screening underway for the phase 1 clinical program.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending approval – Opened PBGENE-HBV phase 1 clinical program in Moldova ; patient screening underway with
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is a treatment being developed for chronic hepatitis B.
Where is the PBGENE-HBV phase 1 trial taking place?
The phase 1 clinical program for PBGENE-HBV is being conducted in Moldova.
What recent approval did Precision BioSciences receive?
They received approval for their first Clinical Trial Application for PBGENE-HBV.
What is the current status of patient screening?
Patient screening for the PBGENE-HBV trial is currently underway.